Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus (Medico-GDM)

Metformin vs Control to Prevent Gestational Diabetes Mellitus (GDM) in Women With a High Risk for GDM, an Open Label Randomized Controlled Trial, The Medico-GDM Trial

Metformin vs Control to prevent gestational diabetes mellitus (GDM) in women with a high risk for GDM, an open label randomized controlled trial' The Medico-GDM trial

Study Overview

• Status: Unknown
• Conditions: Gestational Diabetes Mellitus
• Intervention / Treatment: Drug: Metformin; Other: control diet

Detailed Description

Rationale: GDM is a frequent pregnancy complication1 and associated with complications for mother and child.2 At present, the drug of choice for treatment of GDM is Insulin.3 In the last years several studies documented the use of oral blood glucose lowering medication in GDM. Metformin is an accepted alternative for insulin, with comparable glycemic control and neonatal outcomes.4 In studies with women with polycystic ovarian syndrome (PCOS) who received Metformin during pregnancy, the incidence of GDM is less compared to pregnant women with PCOS without Metformin. These studies were however small and there was no adequate control group.5 Our aim is to study the effect of Metformin on the incidence of GDM in women with a high risk for GDM.

Objective: the primary objective is to compare metformin versus no intervention for incidence of GDM in women with a high risk for GDM. The main secondary objective is pregnancy outcome with Metformin, neonatal outcomes and neonatal complications.

Study design: 2 years open label randomized controlled trial, comparing metformin versus control group.

Study population: pregnant women with a high risk of GDM between 18 and 40 years old in the first trimester of pregnancy.

Intervention: the first group receives Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. The second group receives no intervention. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.

Main study parameters/endpoints: the main study parameter is the difference in incidence of GDM between the two groups.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: the subjects will visit our centre for the first time between 12 and 14 weeks of pregnancy, then blood samples will be collected. Further on they will visit our centre at 24 weeks to perform an oral glucose tolerance test (OGTT). Women with GDM in history will perform an OGTT at 16 weeks for the first time. If the OGTT is borderline normal, it will repeated every 4 weeks. This is according to current Dutch guidelines3, without any extra discomfort for study participants. The subjects will visit their own gynaecologist or obstretican for their regular pregnancy controls. Metformin is not officially registered for use in pregnancy. Long term effects for the unborn child are not known. However, previous studies did not found neonatal and pregnancy related complications.

• Study Type: Interventional
• Enrollment (Anticipated): 400
• Phase: Phase 3

Contacts and Locations

Study Locations

• Netherlands
  • Rotterdam, Netherlands
    • Recruiting
    • Maasstad Ziekenhuis
    • Contact: Huguette Brink, Drs; Phone Number: +31 10 291 2889; Email: brinkH@maasstadziekenhuis.nl
    • Contact: Wetenschapsbureau; Phone Number: +31 10 291 3357; Email: wetenschapsbureau@maasstadziekenhuis.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

a subject must meet all of the following criteria:

• high risk (according to ductch national criteria) for gestational diabetes
• aged between 18 and 40 years
• gestational age between 8 and 12 weeks
• and able to communicate and read in Dutch.

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

• no singleton pregnancy judged by ultrasonography
• diagnosis of diabetes mellitus before the current pregnancy-
• high fasting glucose at first trimester (> 5.3 mmol/l)
• cardiac insufficiency-\
• renal insufficiency (MDRD < 60)
• liver disease
• use of medication other than Paracetamol or vitamins and incompetent women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: intervention; Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.	Drug: Metformin; Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery); Other: control diet; 2000 calories/day diet, with an adequate distribution of carbohydrates during the day
Active Comparator: control diet; a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.	Other: control diet; 2000 calories/day diet, with an adequate distribution of carbohydrates during the day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
incidence of gestational diabetes mellitus in both groups	from 14 weeks pregnancy untill delivery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maternal outcomes	Maternal: pregnancy induced hypertension (yes vs no: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), weight gain during pregnancy (kg), abnormal glucose daily curve after pregnancy (yes vs no: measurement of blood glucose concentration seven times daily).), insulin therapy required.	from 14 weeks pregnancy untill delivery
Neonatal outcomes	head circumference (cm), birth weight (g) and height (cm), pH of umbilical-cord. Neonatal complications: serious neonatal complications (including: severe birth defects, stillbirth, birth trauma, respiratory distress, admission to neonatal intensive care unit, low 5-minutes Apgar score (< 7) and premature birth (< 37 weeks of gestation)), neonatal hypoglycaemia that requires therapy, need for phototherapy, small for gestational age (birth weight < 2 SD units), birth weight > 90th percentile, birth weight < 10th percentile.	from 14 weeks pregnancy untill delivery

Collaborators and Investigators

• Sponsor: Maasstad Hospital
• Investigators: Principal Investigator: Joke van der Linden, dr., Maasstad Hospital

Study record dates

Study Major Dates

• Study Start: September 1, 2014
• Primary Completion (Anticipated): September 1, 2016
• Study Completion (Anticipated): September 1, 2017

Study Registration Dates

• First Submitted: October 23, 2014
• First Submitted That Met QC Criteria: October 24, 2014
• First Posted (Estimate): October 27, 2014

Study Record Updates

• Last Update Posted (Estimate): December 28, 2015
• Last Update Submitted That Met QC Criteria: December 24, 2015
• Last Verified: December 1, 2015

More Information

Terms related to this study

• Keywords: prevention; metformin
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Pregnancy Complications; Diabetes Mellitus; Diabetes, Gestational; Hypoglycemic Agents; Physiological Effects of Drugs; Metformin
• Other Study ID Numbers: NL48005.101.15; 2014-000446-30 (EudraCT Number)